Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-019714
Filing Date
2023-03-17
Accepted
2023-03-17 16:50:20
Documents
1
Period of Report
2023-03-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6201
  Complete submission text file 0001209191-23-019714.txt   7625
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Issuer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVENUE, SUITE 300E WASHINGTON DC 20037
Business Address
Honore Tage (Reporting) CIK: 0001967946 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34186 | Film No.: 23743416